News | April 10, 2007

Kensey Nash Embolic Protection System Approved in Europe for Carotid Procedures

April 11, 2007 — Kensey Nash Corp. has announced it has received CE Mark approval to expand the indication for the third generation of its embolic protection technology, known as the TriActiv ProGuard System, for use in the carotid anatomy.

The new indication is significant for the Kensey Nash device in the European marketplace because the use of embolic protection devices is very prominent in carotid stenting procedures. The company had launched the TriActiv ProGuard System in Europe for use in saphenous vein graft procedures last year.

The product line incorporates Local Flush and eXtraction (LFX(TM)) technology designed for use in branched anatomy, such as those of the carotid arteries. The TriActiv ProGuard System incorporates three features designed to reduce the incidence of embolic stroke during carotid stenting procedures — a balloon protection guide wire, a flush catheter, and an automated extraction system to remove debris. The system has been clinically studied and can be used in combination with any approved carotid stent in the marketplace.

To support the CE Mark, Kensey Nash had completed a pilot trial to study the safety of the TriActiv ProGuard device in carotid patients at 5 sites in the U.S. and Europe.

A 50-patient pilot trial at five U.S. European sites supports the CE mark and studied the device’s safety. The data showed no incidence of major strokes or death. Kensey Nash is also currently enrolling patients in the PROGUARD Carotid Pivotal Study, a 300-400 patient registry, the results of which are intended to support FDA clearance.

For more information visit www.kenseynash.com.

Related Content

The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices | October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices | October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices | September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices | September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices | August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices | April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices | March 22, 2017
March 22, 2017 — Two U.S.
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices | September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices | September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
InspireMD, CGuard, PARADIGM study, EuroPCR 2015, Musialek

Image courtesy of InspireMD

News | Embolic Protection Devices | June 23, 2015
InspireMD Inc. announced that its CGuard embolic prevention system reported positive results in the PARADIGM study at...
Overlay Init